• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT DIAGNOSTICS SCARBOROUGH INC. DETERMINE HIV - 1/2 AG/AB COMBO; IVD FOR HIV 1/2 AG/AB

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT DIAGNOSTICS SCARBOROUGH INC. DETERMINE HIV - 1/2 AG/AB COMBO; IVD FOR HIV 1/2 AG/AB Back to Search Results
Catalog Number 7D2648
Device Problems False Positive Result (1227); Incorrect, Inadequate or Imprecise Result or Readings (1535)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Type  malfunction  
Manufacturer Narrative
The investigation is still in process.A supplemental report will be submitted after completion.Please see related mfr report # 1221359-2020-00401.
 
Event Description
A customer reported 2 (b)(6) results with the determine hiv 1/2 ag/ab combo 25t.This report represents patient two (2) of two (2).The customer reported the results as p-24 antigen (ag) positive.Sample information was not provided.Confirmatory testing results (not specified) were (b)(6).No further patient information was provided.There was no death based on the determine hiv 1/2 ag/ab combo results.The alere hiv 1/2 ag-ab product insert indicates reactive test results should be confirmed by additional testing using other tests.Specimens from individuals with toxoplasma igg, human anti-mouse antibodies, rheumatoid factor, elevated triglycerides (above 600 mg/dl), herpes simplex virus infection, hospitalized, and cancer patients may give (b)(6) test results.When the source patient is ag and/or ab (b)(6), and receives unnecessary short-term art treatment, the risk of short- and medium-term toxicity with the current recommended art prophylaxis regimen is primarily transient metabolic abnormalities, which appear to be primarily mild and reversible after treatment is interrupted.As the sex and/or pregnancy status of the patient is unknown, given that the risk of short and medium-term toxicity to a possible fetus is unknown, this case shall be reported.
 
Manufacturer Narrative
Additional information was received on 24nov2020 that identified the patient as a female confirmed to not be pregnant (confirmed (b)(6) 2020).Based on this information this event is no longer reportable.Risk of short- and medium-term toxicity to patient with the current recommended art prophylaxis regimens is primarily transient metabolic abnormalities which appears to be primarily mild and reversible after treatment is interrupted.The risk will not cause or contribute to a death or serious injury and is therefore considered not reportable.Additional information: a3.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
DETERMINE HIV - 1/2 AG/AB COMBO
Type of Device
IVD FOR HIV 1/2 AG/AB
Manufacturer (Section D)
ABBOTT DIAGNOSTICS SCARBOROUGH INC.
10 southgate road
scarborough ME 04074
MDR Report Key10904435
MDR Text Key221017839
Report Number1221359-2020-00404
Device Sequence Number1
Product Code MZF
Combination Product (y/n)N
PMA/PMN Number
BP120037
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional
Type of Report Initial,Followup
Report Date 12/23/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/25/2020
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Catalogue Number7D2648
Date Manufacturer Received11/24/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
-
-